ASM-Binding Antibody Design for Direct Protein Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases like Alzheimer's and depression, which target the ASM protein, suffer from side effects due to indirect inhibition methods, necessitating the development of direct and specific inhibitors.
Innovation Solution
Development of antibodies and antigen-binding fragments that specifically bind to the ASM protein, along with methods for producing and detecting these molecules, including nucleic acids, expression vectors, and host cells for their production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tricyclic antidepressants are used to inhibit ASM protein activity, then the expression or activity of ASM protein is inhibited, but side effects occur such as blurred vision, increased light sensitivity, and vomiting
Solution Approach 1:
The patent extracts and isolates the specific therapeutic function of inhibiting ASM protein from the complex mechanism of tricyclic antidepressants. By developing antibodies that specifically target and bind to ASM protein, the invention separates the desired inhibitory effect from the unwanted side effects caused by broad neurotransmitter reuptake inhibition, achieving selective ASM inhibition without affecting other nervous system functions.
Solution Approach 2:
The patent introduces antibodies as intermediary molecules that specifically recognize and bind to ASM protein. These antibodies act as selective mediators that inhibit ASM activity through direct binding, replacing the non-specific neurotransmitter reuptake inhibition mechanism of tricyclic antidepressants. This intermediary approach enables precise targeting of ASM protein while avoiding off-target effects on other nervous system components.
2Reliability
If indirect inhibitors are used to reduce ASM protein expression, then ASM activity is reduced, but the mechanism is complex and less specific
Solution Approach 1:
The patent extracts the essential function of ASM inhibition from complex indirect mechanisms and implements it through a direct, simple mechanism. By using antibodies that bind directly to ASM protein, the invention eliminates multi-step indirect pathways and achieves ASM inhibition through a single, well-defined molecular interaction, thereby simplifying the overall mechanism while maintaining therapeutic effectiveness.
Solution Approach 2:
The patent changes the fundamental parameter of the inhibition mechanism from indirect gene expression modulation to direct protein binding. This parameter change transforms a complex, multi-level regulatory process into a simple, direct molecular interaction that can be precisely controlled and measured, reducing mechanistic complexity while achieving reliable ASM activity reduction.
Data Source
AI summary
The present disclosure relates to an antibody specifically binding to an acid sphingomyelinase (ASM) protein and, specifically, the antibody or antigen-binding fragment according to the present disclosure specifically binds to an ASM protein with high affinity and thus can be used in detecting the ASM protein or diagnosing a disease occurring due to the over-expression of the ASM protein.